US Patent No: 6,676,967

Number of patents in Portfolio can not be more than 2000

Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia

Stats

See full text
ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods for reducing flushing in individuals being treated for hyperlipidemia with nicotinic acid are disclosed. According to the methods of the present invention, flushing can be reduced in individuals under going nicotinic acid therapy without causing drug-induced hepatotoxicity to a level that would require the nicotinic acid therapy to be discontinued by orally administering to the individuals intermediate nicotinic acid formualtions having unique biopharmaceutical characteristics as a single dose once per day. While the methods of the present invention contemplate administering the intermediate release nicotinic acid formulations at any time during a 24 hour period, it is preferable to administer them once-a-day as a single dose during the evening or at night between about 6:00 pm. and 12:00 a.m., preferably between about 8:00 p.m. and 12:00 a.m., and most preferably between about 8:00 p.m. and 10:00 p.m.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ABBOTT LABORATORIESABBOTT PARK, IL2698
ABBOTT RESPIRATORY LLCABBOTT PARK, IL4

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bova, David J Hollywood, FL 29 46
Cefali, Eugenio A Fort Lauderdale, FL 15 86

Cited Art Landscape

Patent Info (Count) # Cites Year
 
American Cyanamid Company (10)
4,348,399 Antiatherosclerotic and hypolipidemic 4-(monoalkylamino)phenyl alkane, alkene and alkyne carbinols, aldehydes, carboxylic acids and derivatives 20 1978
4,230,878 Hypolipidemic and antiatherosclerotic 4-[(cyclopropyl alkyl)amino]benzoic acids and derivatives 6 1978
4,205,085 Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds 10 1978
4,211,783 Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds 15 1978
4,382,143 Hypolipidemic and antiatherosclerotic novel (monosubstituted-amino)heteroaryl carboxylic acids and analogs 24 1979
4,305,959 Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds 7 1979
4,310,545 Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds 12 1979
4,318,914 Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds 7 1979
4,485,105 Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides 25 1980
4,440,940 Anti-atherosclerotic agents 20 1981
 
MERCK & CO., INC. (10)
4,795,644 Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins 55 1987
4,814,183 Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins 45 1987
4,997,658 Method for enhancing the lowering of plasma cholesterol levels 13 1988
5,049,696 Antihypercholesterolemic compounds 8 1989
5,009,895 Sustained release with high and low viscosity HPMC 24 1990
5,010,105 Antihypercholesterolemic compounds 8 1990
5,182,298 Cholesterol lowering agents 17 1991
5,262,435 Cholesterol lowering compounds 17 1992
5,258,401 Cholesterol lowering compounds 10 1992
5,256,689 Cholesterol lowering compounds 13 1992
 
ALZA CORPORATION (8)
4,203,439 Osmotic system with volume amplifier for increasing amount of agent delivered therefrom 98 1978
4,256,108 Microporous-semipermeable laminated osmotic system 360 1979
4,326,525 Osmotic device that improves delivery properties of agent in situ 103 1980
4,576,604 Osmotic system with instant drug availability 97 1983
4,673,405 Osmotic system with instant drug availability 52 1986
4,871,548 Controlled release dosage form comprising different cellulose ethers 69 1987
4,851,232 Drug delivery system with means for obtaining desirable in vivo release rate pattern 45 1987
4,915,952 Composition comprising drug, HPC, HPMC and PEO 15 1989
 
E. R. Squibb & Sons, Inc. (8)
4,505,890 Controlled release formulation and method 22 1983
4,610,870 Controlled release formulation 76 1984
4,756,911 Controlled release formulation 81 1986
4,792,452 Controlled release formulation 98 1987
5,130,333 Method for treating type II diabetes employing a cholesterol lowering drug 44 1990
5,169,638 Buoyant controlled release powder formulation 89 1991
5,190,970 Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor 34 1991
5,260,305 Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination 29 1992
 
FOREST LABORATORIES, INC. (8)
4,226,849 Sustained release therapeutic compositions 75 1979
4,357,469 Carrier base material for prolonged release therapeutic compositions 39 1981
4,369,172 Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose 217 1981
4,389,393 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose 225 1982
4,795,327 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants 34 1984
4,540,566 Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose 66 1984
4,849,229 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants 28 1988
4,983,398 Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates 24 1988
 
Warner-Lambert Company (8)
4,285,951 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentyl ester of 3-pyridine carboxylic acid and use as an anti-atherosclerotic agent 10 1979
4,747,881 Ingestible aggregate and delivery system prepared therefrom 107 1985
4,814,354 Lipid regulating agents 33 1986
4,851,233 Sustained release formulations 13 1986
4,789,549 Sustained release dosage forms 27 1987
4,950,689 Pectin delivery system 18 1987
5,030,653 Antihyperlipidemic and antiatherosclerotic compounds and compositions 15 1990
5,167,964 Semi-enteric drug delivery systems and methods for preparing same 69 1992
 
SCHERING CORPORATION (6)
4,282,233 Antihistaminic 11-(4-piperidylidene)-5H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridines 102 1980
4,695,591 Controlled release dosage forms comprising hydroxypropylmethylcellulose 43 1985
4,657,757 Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate 14 1985
4,990,535 Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine 51 1989
5,100,675 Sustained release tablet comprising loratadine, ibuprofen and pseudoephedrine 51 1990
5,262,165 Transdermal nitroglycerin patch with penetration enhancers 25 1992
 
ELAN PHARMA INTERNATIONAL LIMITED (5)
4,940,588 Controlled release powder and process for its preparation 141 1988
4,952,402 Controlled release powder and process for its preparation 177 1988
5,015,479 Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine 39 1988
4,973,469 Drug delivery system 58 1989
5,128,142 Sustained release drug delivery system 44 1989
 
The Dow Chemical Company (4)
4,678,516 Sustained release dosage form based on highly plasticized cellulose ether gels 60 1984
4,734,285 Sustained release compositions 36 1985
4,704,285 Sustained release compositions comprising hydroxypropyl cellulose ethers 60 1985
5,039,341 Binder composition comprises a blend of a high viscosity and low viscosity hydroxypropyl methylcellulose ether, and a tape joint composition containing such binder 19 1989
 
Verex Laboratories, Inc. (4)
4,375,468 Constant order release aspirin composition and method of treating arthritis 34 1982
4,461,759 Constant release rate solid oral dosage formulations of veropamil 33 1983
4,522,804 Constant release rate solid oral dosage formulations of propranolol 13 1984
4,525,345 Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions 28 1984
 
AMERICAN HOME PRODUCTS CORPORATION (3)
4,248,857 Sustained release pharmaceutical compositions 46 1979
4,309,404 Sustained release pharmaceutical compositions 68 1981
5,190,940 Cholesterol ester hydrolase inhibitors 6 1991
 
Aktiebolaget Hassle (2)
4,803,081 New pharmaceutical preparations with extended release 37 1987
4,942,040 Pharmaceutical preparation and a process for its preparation 38 1988
 
BANNER PHARMACAPS, INC. (2)
4,708,834 Preparation of gelatin-encapsulated controlled release composition 72 1986
4,795,642 Gelatin-encapsulated controlled-release composition 55 1987
 
BASF CORPORATION (2)
4,605,666 Process for preparing spray-dried powders containing a water-soluble vitamin and powders prepared thereby 16 1984
4,830,859 Process for lubricating water-soluble vitamin powders 8 1987
 
BRISTOL-MYERS SQUIBB COMPANY (2)
5,011,947 Antihypercholesterolemic alkylene compounds 10 1990
5,110,940 Antihypercholesterolemic tetrazole compounds 6 1991
 
Dr. Karl Thomae GmbH (2)
4,367,217 Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof 52 1980
5,286,736 Pyridyl compounds and pharmaceutical compositions containing these compounds 11 1993
 
EURAND INTERNATIONAL S.P.A. (2)
4,812,316 Process for the preparation of stabilized isosorbide-5-mononitrate tablets, being also of sustained release, and formulations thus obtained 12 1986
5,047,248 Formulation for preparing sustained release drugs for oral administration 29 1989
 
EURO-CELTIQUE S.A. (2)
4,844,907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 110 1986
4,834,965 Controlled release pharmaceutical composition 67 1987
 
FUJISAWA PHARMACEUTICAL CO., LTD. (2)
4,428,951 Long acting pharmaceutical composition 7 1982
4,695,467 Sustained release tablet 57 1985
 
HAUSER-KUHRTS, INC. (2)
5,023,245 Improved niacin formulation 29 1989
5,096,714 Prolonged release drug tablet formulations 37 1989
 
Hoechst Aktiengesellschaft (2)
4,792,554 Pyridine compounds, pharaceutical compositions, their use in allergy therapy 9 1986
4,935,246 Process for the coating of granules 103 1988
 
MERZ + CO. GMBH & CO. (2)
RE32581 Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same for treatment of hyperlipidemia 13 1984
4,758,581 Pyridyl N-oxides 6 1987
 
NATIONAL BIOSOURCE, INC., A CORP. OF CA. (2)
4,911,917 Cholesterol-lowering combination comopsitions of magnesium salt and niacin 13 1988
4,965,252 Cholesterol-lowering combination compositions of guar gum and niacin 19 1988
 
NIKKEN CHEMICALS CO., LTD. (2)
4,261,970 Theophylline sustained release granule 21 1980
4,692,337 Sustained release pharmaceutical tablet of theophylline and production process thereof 28 1984
 
NORTH CAROLINA CENTRAL UNIVERSITY (2)
5,034,528 Compositions for the control of hyperlipidemia 7 1988
4,946,963 Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones 6 1988
 
PENWEST PHARMACEUTICALS CO. (2)
4,994,276 Directly compressible sustained release excipient 70 1988
5,169,639 Controlled release verapamil tablets 34 1991
 
PURDUE PHARMA L.P. (2)
4,828,836 Controlled release pharmaceutical composition 146 1987
4,834,985 Controlled release pharmaceutical composition 175 1987
 
REID-ROWELL, INC., 640 TENTH STREET, ATLANTA, GEORGIA 30318, A GEORGIACORP. (2)
4,539,198 Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range 41 1983
4,690,824 Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range 16 1985
 
Roussel Uclaf (2)
4,432,966 Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating 79 1982
4,478,819 Novel oral preparations 41 1983
 
Smith Kline & French Laboratories Limited (2)
5,169,640 Pharmaceutical compositions 23 1989
5,188,839 Pharmaceutical compositions of cimetidine 20 1989
 
Syntex Pharmaceuticals, Ltd. (2)
4,571,333 Controlled release naproxen and naproxen sodium tablets 48 1983
4,803,079 Controlled release naproxen and naproxen sodium tablets 50 1985
 
TCF BANK SAVINGS FSB N/K/A TCF NATIONAL BANK (2)
5,126,145 Controlled release tablet containing water soluble medicament 103 1990
5,268,181 Method of using niacin to control nocturnal cholesterol synthesis 19 1992
 
TEIJIN LIMITED (2)
4,755,544 Sustained release preparation 49 1986
4,729,895 Composition for solid pharmaceutical preparations of active vitamins D.sub.3 25 1987
 
ADD ADVANCED DRUG DELIVERY TECHNOLOGIES AG (1)
4,992,278 Therapeutic system for sparingly soluble active ingredients 31 1989
 
ALFA WASSERMANN S.P.A. (1)
4,888,178 Galenic formulations with programmed release containing naproxen 25 1989
 
ALRA LABORATORIES, INC., GURNEE, ILLINOIS (1)
4,684,516 Sustained release tablets and method of making same 44 1985
 
ANHEUSER-BUSCH, INC. (1)
4,251,519 Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels 28 1979
 
BASF AKTIENGESELLSCHAFT (1)
4,925,905 Preparation of water-soluble copolymers based on monoethylenically unsaturated carboxylic acids 10 1989
 
BAYER HEALTHCARE AG (1)
4,892,741 Press coated DHP tablets 61 1988
 
BIO-DAR LTD. (1)
4,749,575 Microencapsulated medicament in sweet matrix 127 1986
 
BOEHRINGER INGELHEIM INTERNATIONAL GMBH (1)
4,361,546 Retard form of pharmaceuticals with insoluble porous diffusion coatings 34 1981
 
Boehringer Ingelheim KG (1)
4,547,359 Divisible pharmaceutical tablet with delayed active ingredient release 16 1984
 
Buhk Meditec A/A (1)
5,213,808 Controlled release article with pulsatile release 144 1990
 
CARDINAL ASSOCIATES, INC. DBA BERGSTROM NUTRITION (1)
4,568,547 Solid pharmaceutical compositions comprising MSM and their production 32 1984
 
CHUGAI SEIYAKU KABUSHIKI KAISHA (1)
4,454,108 Prolonged-action multiple-layer tablets 26 1982
 
CIBA-GEIGY CORPORATION (1)
4,353,887 Divisible tablet having controlled and delayed release of the active substance 51 1980
 
CLEAR LAKE DEVELOPMENT GROUP, 201 N. MAIN, WICHITA, KN., 67202 A PARTNERSHIP (1)
4,457,907 Composition and method for protecting a therapeutic drug 96 1982
 
CLINICAL DIAGNOSTIC SYSTEMS INC. (1)
4,283,382 Fluorescent labels comprising rare earth chelates 59 1978
 
DEGUSSA-HULS AKTIENGESELLSCHAFT (1)
4,959,478 Method of producing-coarse crystalline nicotinic acid with a high degree of purity 7 1989
 
DRUGTECH CORPORATION (1)
5,133,974 Extended release pharmaceutical formulations 231 1990
 
Eli Lilly and Company (1)
4,968,508 Sustained release matrix 67 1989
 
Evreka, Inc. (1)
4,362,711 Blood cholesterol level reducing agent and method 23 1980
 
FARVALSA A.G. (1)
4,837,032 Theophylline sustained release tablet 18 1986
 
FIRST NATIONAL BANK OF GRAPEVINE (1)
5,002,774 Sustained release pharmaceutical tablet 17 1989
 
GIST-BROCADES N.V. (1)
5,211,958 Pharmaceutical composition and process for its preparation 18 1992
 
GLAXO GROUP LIMITED (1)
5,278,067 Cyclic ketal derivatives 6 1992
 
HERCULES INCORPORATED (1)
4,759,923 Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives 106 1987
 
HITACHI MAXELL, LTD. (1)
4,695,910 Recording disc cartridge having an improved hub assembly 21 1984
 
Interferon Sciences, Inc. (1)
4,744,907 Blood cell separation 7 1987
 
Key Pharmaceuticals, Inc. (1)
4,556,678 Sustained release propranolol tablet 36 1982
 
KNOLL PHARMACEUTICAL COMPANY (1)
4,308,251 Controlled release formulations of orally-active medicaments 54 1980
 
LIPOGENICS, INC. (1)
4,603,142 Cholesterol lowering method of use 47 1984
 
LOTTE CO., LTD. (1)
5,171,570 Substance having suppressing function for diseases relating to increase in cholesterol, and foods and drinks in which it is used 15 1990
 
Mead Johnson & Company (1)
4,465,660 Sustained release tablet containing at least 95 percent theophylline 22 1982
 
MEMORIAL UNIVERSITY OF NEWFOUNDLAND (1)
4,775,483 Method to reduce plasma cholesterol 36 1986
 
MERCK SHARP & DOHME CORP. (1)
5,314,697 Stable extended release oral dosage composition comprising loratadine and pseudoephedrine 37 1992
 
Mitsubishi Petrochemical Co., Ltd. (1)
4,777,042 Cholesterol level-lowering agents 23 1987
 
MITSUI TOATSU CHEMICALS, INC. (1)
4,713,245 Granule containing physiologically-active substance, method for preparing same and use thereof 43 1985
 
MOUNT SINAI SCHOOL OF MEDICINE (1)
4,279,898 In vivo inhibitors of cholesterol biosynthesis 6 1980
 
Neo-Bionics, Inc. (1)
4,472,436 Increasing HDL-cholesterol levels with phenylethylamine derivatives 8 1982
 
NESTEC S.A. (1)
4,999,380 Treatment of lipoprotein disorders associated with cholesterol metabolism 9 1988
 
NISSAN CHEMICAL INDUSTRIES, LTD. (1)
4,624,950 Method for treating atherosclerosis hyperlipidema, lipid deposition on arterial walls, or raising the ratio of high density lipoprotein cholesterol to total cholesterol in serum 7 1984
 
NISSHIN SEIFUN GROUP INC. (1)
5,025,012 Nicotinic acid derivatives and pharmaceutical compositions comprising same 32 1990
 
Norwich Eaton Pharmaceuticals, Inc. (1)
5,032,406 Dual-action tablet 44 1989
 
NOVARTIS CONSUMER HEALTH, INC. (1)
4,752,479 Multi vitamin and mineral dietary supplement with controlled release bioavailable iron 63 1986
 
NOVARTIS;CORPORATE INTELLECTUAL PROPERTY (1)
4,857,336 Oral therapeutic system having systemic action 40 1987
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (1)
4,973,468 Skin permeation enhancer compositions 65 1989
 
PAUL ROYALTY FUND, L.P. (1)
4,839,177 System for the controlled-rate release of active substances 107 1986
 
PEDINOL PHARMACAL INC. (1)
4,753,801 Sustained release tablets 46 1985
 
PHARMACIA & UPJOHN COMPANY (1)
4,824,677 Grooved tablet for fractional dosing of sustained release medication 29 1986
 
PIERRE FABRE MEDICAMENT (1)
5,132,116 Tablets of the hydrophilic matrix type based on salbutamol and a process for their preparation 28 1991
 
REXALL SHOWCASE INTERNATIONAL, INC. (1)
4,824,672 Method and composition for reducing serum cholesterol 49 1986
 
RHODIA INC. (1)
4,710,519 Process for preparing spray dried acetaminophen powder and the powder prepared thereby 20 1985
 
RHONE-POULENC RORER PHARMACEUTICALS INC. (1)
4,994,267 Transdermal acrylic multipolymer drug delivery system 85 1989
 
ROQUETTE FRERES (1)
5,264,226 Process for preparing dairy products with a low content of sterols, particularly of cholesterol 16 1991
 
SHOWA DENKO K.K. (1)
4,842,863 Granular agent for ruminant and production method thereof 42 1988
 
Siegfried Aktiengesellschaft (1)
4,182,902 Novel cholesterol-lowering compounds 7 1978
 
SIGMA-TAU INC. (1)
4,255,449 Method of treating abnormal lipoprote in ratios 22 1979
 
SINNREICH TECHNOLOGIEN GMBH (1)
4,996,058 Covered retard forms 83 1988
 
Sterling Drug Inc. (1)
4,970,081 Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith 17 1989
 
Syntex (U.S.A.) Inc. (1)
4,452,775 Cholesterol matrix delivery system for sustained release of macromolecules 147 1982
 
SYNTHETIC BLOOD CORPORATION (1)
4,963,367 Drug delivery compositions and methods 234 1987
 
TERUMO KABUSHIKI KAISHA (1)
4,794,115 Method of treating hyperlipemia 6 1986
 
The Procter & Gamble Company (1)
5,116,610 Compositions for treating hypercholesterolemia 15 1991
 
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (1)
4,866,058 Method for control of hyperlipidemia 8 1988
 
TOSOH CORPORATION (1)
5,178,854 Cholesterol-lowering agents 9 1991
 
Unimed, Inc. (1)
4,291,030 Method of lowering blood cholesterol 9 1980
 
Union Carbide Corporation (1)
4,946,870 Delivery systems for pharmaceutical or therapeutic actives 121 1988
 
VIRGINIA COMMONWEALTH UNIVERSITY OF RICHMOND, VA (1)
4,920,115 Method of lowering LDL cholesterol in blood 33 1988
 
WILLIAM HARVEY STIFTUNG FUR FORSCHUNG UND AUSBILDUNG (1)
4,237,118 Dietary supplement and dietary methods employing said supplement for the treatment of obesity 40 1976
 
WYETH (1)
4,966,768 Sustained release etodolac 26 1988
 
ZAMBON GROUP S.P.A. (1)
5,196,440 Compounds active as inhibitors of the cholesterol biosynthesis 11 1990
 
Zumbro Enterprises, Inc. (1)
4,696,762 Hydroxypropylmethylcellulose 17 1985
 
ZYMA SA (1)
4,784,858 Controlled release tablet 58 1986
 
Zyna SA (1)
4,886,669 Galenical formulation 49 1987
 
Other [Check patent profile for assignment information] (12)
4,259,314 Method and composition for the preparation of controlled long-acting pharmaceuticals 109 1979
4,272,548 Process for the lowering of increased levels of cholesterol and neutral fat in the blood of humans 18 1980
4,268,524 Method of treating abnormal lipoprotein ratios with acylcarnitine 11 1980
4,455,298 Pharmaceutical preparations with gastro-protective action 16 1982
4,680,323 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration 35 1983
4,764,374 Pharmaceutical composition based on guar gum and other antacids for protection of the oesogastroduodenal mucous membrane 13 1986
4,775,535 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 22 1986
4,882,167 Dry direct compression compositions for controlled release dosage forms 67 1987
4,855,143 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 21 1988
4,920,123 Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals 14 1988
5,110,817 Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals 11 1990
5,145,678 Method of reducing blood serum cholesterol 13 1991

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
CORTRIA CORPORATION (2)
8,211,922 1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities 0 2010
8,481,570 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities 0 2012
 
PHARMENA SPOLKA AKCYJNA (PHARMENA S.A.) (2)
7,935,717 Method for treating hypertriglyceridemia, dyslipidemia and hypercholesterolemia with a 1-methylnicotinamide salt 0 2005
8,124,631 Use of quaternary pyridinium salts as vasoprotective agents 0 2010
 
KOS LIFE SCIENCES, INC. (1)
7,998,506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 0 2003
 
LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (1)
8,658,160 Composition and method for cancer chemoprevention 0 2007

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 13, 2015
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00